API supply concerns from China fuel Alembic Pharma’s global prospects
May 04, 2021
Company’s segment revenues surge 35% during the year The Covid-led supply disruptions of Active Pharmaceutical Ingredients (API) from China last year has proved to be a blessing in disguise for Alembic Pharma.
The API revenues of the Indian drug major during fiscal 2020-21 jumped by 35 per cent following international buyers’ preference for ‘China-plus-one’ strategy to secure key medical inputs.
API shortage after Chinese supply disruptions early in 2020 had triggered concerns across the markets for a possible shortage of the raw materials.
Speaking to BusinessLine, Pranav Amin, MD, Alembic Pharmaceuticals Ltd, said, “This (API supply disruptions from China) gave an impetus to our API business globally. After second half of the year, Chinese were back in the market and there was competition again. (But) we had secured some markets with existing customers, who adopted a China-pl
Alembic Pharmaceuticals Limited (APL) has posted a 12 per cent growth in net profit for the quarter ended March 31, to Rs 251 crore, from Rs 225 crore during the corresponding period last year. The company s net sales were up six per cent to Rs 1,280 crore, from Rs 1,207 crore. On a full-year basis, the company s net profit rose 42 per cent to Rs 1,178 crore for FY21, from Rs 829 crore in FY20, while net sales were up 17 per cent to Rs 5,393 crore (Rs 4,606 crore). Commenting on the results, Alembic Pharmaceuticals Limited managing director Pranav Amin said the fiscal was an outstanding year , with the company recording its highest-ever sales and profit. This was led by strong growth in the API and international businesses. The operating teams worked tirelessly through the pandemic to ensure critical supplies were uninterrupted, Amin added.
Alembic Pharmaceuticals Ltd Q4FY21 consolidated net profit drops QoQ to Rs 237 41 crores equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
Alembic Pharmaceuticals rose 1.67% to Rs 999.40 after the company s consolidated net profit jumped 12% to Rs 251 crore on 6% increase in net sales to Rs 1,280 crore in Q4 FY21 over Q4 FY20.On a consolidated basis, the company s net profit jumped 42% to Rs 1178 crore on 17% increase in net sales to Rs 5393 crore in the year ended March 2021 over the year ended March 2020.
International formulations jumped 19% Y-o-Y (year-on-year) to Rs 2,942 crore in FY21 over FY20. US Generics spurted 9% Y-o-Y to Rs 2,163 crore in FY21 over FY20. Ex-US International Formulations soared 57% Y-o-Y to Rs 779 crore in FY21.
13 ANDA s were filed in the quarter and 29 ANDA filings for the year. Research & Department (R&D) spend was reported at 12% of revenue or Rs 670 crore for the year.
State bodies remain personal fiefdoms despite Lodha reforms prokerala.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prokerala.com Daily Mail and Mail on Sunday newspapers.